Zobrazeno 1 - 10
of 114
pro vyhledávání: ''
Autor:
Diana Abbott, Clayton A. Smith, Julie Rosser, Mohd Minhajuddin, Maria L. Amaya, Jeffrey Schowinsky, Daniel A. Pollyea, Anagha Inguva, Craig T. Jordan, Amanda Winters, Christine McMahon, Jonathan A. Gutman, Audrey Sato, Evan Cherry, Marc Schwartz, Shanshan Pei, Brett M. Stevens
Publikováno v:
Blood Advances
Key Points Patients with AML who received IC were compared with those who received ven to investigate predictors of outcomes.Presence of RUNX1 mutations is associated with better outcomes for ven/aza compared with IC.
Visual Abstract
Veneto
Visual Abstract
Veneto
Autor:
P. Andrew Futreal, Ken Furudate, Marina Konopleva, Sanam Loghavi, Guillermo Garcia-Manero, Sa A. Wang, Yuya Sasaki, Gheath Alatrash, Musa Yilmaz, Koji Sasaki, Naveen Pemmaraju, Latasha Little, Tapan M. Kadia, Koichi Takahashi, Farhad Ravandi, Kiyomi Morita, Curtis Gumbs, Jairo Matthews, Feng Wang, Hagop M. Kantarjian, Courtney D. DiNardo, Richard E. Champlin, Naval Daver, Tomoyuki Tanaka
Publikováno v:
Blood
Introduction While clonal hematopoiesis (CH) can precede the development of AML, preleukemic CH can persist after attaining remission. In rare cases, non-leukemic CH can also emerge after remission. Long-term clonal dynamics of persistent CH or emerg
Autor:
Su Young Kim, Ruby Nandam, Brenda Chyla, Shuo Ma, John Pesko, John F. Seymour, Ahmed Salem, Amanda Jacobson, Michael Y. Choi, Thomas J. Kipps, Andrew W. Roberts, Abdullah A. Masud, Mary Ann Anderson, Jennifer Arzt, Danielle M. Brander, Kathryn Humphrey
Publikováno v:
Blood
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (2
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Oludamilola Olajide, Allison M. Deal, Nilanjan Ghosh, Jeanne F. Noe, Stephen M. Ansell, Thomas C. Shea, Nishitha Reddy, Steven I. Park, Lihua E. Budde
Publikováno v:
Blood Adv
Approximately 90% of limited-stage Hodgkin lymphoma (HL) patients are projected to be cured with standard therapy, but many do not live their expected life span because of late treatment–related complications. New treatment paradigms are needed to
Autor:
Christoffer Flensburg, Piers Blombery, David C.S. Huang, Huaxian Ma, Giovanna Pomilio, Sarah MacRaild, Sanam Loghavi, Rachel Thijssen, Fiona C. Brown, Ian J. Majewski, Jessica M. Salmon, Ing Soo Tiong, Hagop M. Kantarjian, Adam Ivey, Xufeng Chen, Keyur P. Patel, Ioannis Aifantis, A. Quaglieri, Shaun Fleming, Courtney D. DiNardo, Zhen Xu, Andrew W. Roberts, Marina Konopleva, Nik Cummings, Qi Zhang, Andrew H. Wei, Steve Kornblau, Chong Chyn Chua, Christina Glytsou
Publikováno v:
Blood. 135:791-803
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based com
Autor:
Sanjeet Dadwal, Jianying Zhang, David S. Snyder, Matthew Mei, Stephen J. Forman, Haris Ali, Karamjeet S. Sandhu, Bernard Tegtmeier, Ahmed Aribi, Vinod Pullarkat, Samer K. Khaled, Amandeep Salhotra, Monzr M. Al Malki, Shukaib Arslan, Ibrahim Aldoss, Anthony S. Stein, Guido Marcucci, Ryotaro Nakamura
Publikováno v:
Blood Advances. 3:4043-4049
The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML). Treatment with VEN-HMAs results in prolonged cytopenia, thereby exposing pat
Autor:
Brett M. Stevens, Mark D. Ewalt, Diana Abbott, Daniel A. Pollyea, Stephanie Chase, Jennifer Tobin, Molly Nakic, Chelsey Boggs, Jeffrey Schowinsky, Bradford Siegele, Steven R. Schuster, Jonathan A. Gutman, Keri Halsema, Enkhtsetseg Purev, Lindsey Lyle, Jeff Kaiser, Clayton A. Smith, Amanda Winters, Julie Rosser, Craig T. Jordan, Vishal Rana
Publikováno v:
Blood Advances. 3:2911-2919
Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our single-institution off-label experience with venetoclax/azacitidine, comparing outcomes with a cli
Autor:
Andrew M. Evens, Paul M. Barr, Ann S. LaCasce, Sonali M. Smith, Michael V. Knopp, John P. Leonard, Deborah M. Stephens, David J. Straus, Hongli Li, Michael LeBlanc, Lisa M. Rimsza, Craig H. Moskowitz, Brad S. Kahl, Jonathan W. Friedberg, Heiko Schöder, Eric D. Hsi, Nancy L. Bartlett
Publikováno v:
J Nucl Med
Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)-adapted therapy on S0816 (NCT00822120). Patients received 2 cycles of doxorubicin, ble
Autor:
Stephan Stilgenbauer, Lang Zhou, Su Young Kim, Shuo Ma, Michael Hallek, Kathryn Humphrey, Barbara Eichhorst, Brenda Chyla, Andrew W. Roberts, John C. Byrd, Steven Coutre, John F. Seymour, Thomas J. Kipps, Jalaja Potluri, Matthew S. Davids, William G. Wierda, Maria Verdugo, Jacqueline Nielsen
Publikováno v:
Blood. 134:111-122
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enro